Repository logo

Predicting treatment resistance from first-episode psychosis using routinely collected clinical information

Accepted version

No Thumbnail Available



Change log


Osimo, Emanuele 
Perry, Benjamin 
Mallikarjun, Pavan 
pritchard, megan 
Lewis, Jonathan 


Around a quarter of people who experience a first episode of psychosis (FEP) will develop treatment-resistant schizophrenia (TRS), but there are currently no established clinically useful methods to predict this from baseline. We aimed to explore the predictive potential for clozapine use as a proxy for TRS of routinely collected, objective biomedical predictors at FEP onset, and to externally validate the model in a separate clinical sample of people with FEP. We developed and externally validated a forced-entry logistic regression risk prediction Model fOr cloZApine tReaTment, or MOZART, to predict up to 8-year risk of clozapine use from FEP using routinely recorded information including age, sex, ethnicity, triglycerides, alkaline phosphatase levels, and lymphocyte counts. We also produced a least-absolute shrinkage and selection operator (LASSO) based model, additionally including neutrophil count, smoking status, body mass index, and random glucose levels. The models were developed using data from two UK psychosis early intervention services (EIS) and externally validated in another UK EIS. Model performance was assessed via discrimination and calibration. We developed the models in 785 patients, and validated externally in 1,110 patients. Both models predicted clozapine use well at internal validation (MOZART: C 0.70; 95%CI 0.63,0.76; LASSO: 0.69; 95%CI 0.63,0.77). At external validation, discrimination performance reduced (MOZART: 0.63; 0.58,0.69; LASSO: 0.64; 0.58,0.69) but recovered after re-estimation of the lymphocyte predictor (C: 0.67; 0.62,0.73). Calibration plots showed good agreement between observed and predicted risk in the forced-entry model. We also present a decision-curve analysis and an online data visualisation tool. The use of routinely collected clinical information including blood-based biomarkers taken at FEP onset can help to predict the individual risk of clozapine use, and should be considered equally alongside other potentially useful information such as symptom scores in large-scale efforts to predict psychiatric outcomes.



Schizophrenia, Brain Disorders, Mental Health, Prevention, Clinical Research, Mental health, 3 Good Health and Well Being

Journal Title

Nature Mental Health

Conference Name

Journal ISSN


Volume Title


Nature Research
Department of Health (via National Institute for Health Research (NIHR)) (DRF-2018-11-ST2-018)
Evelyn Trust (22-Feb)
Wellcome Trust (201486/Z/16/Z)
Medical Research Council (MC_PC_17213)
MQ: Transforming Mental Health (MQDS17\40)
Medical Research Council (MR/S037675/1)
National Institute for Health Research (IS-BRC-1215-20014)
Medical Research Council (MR/W014386/1)